GLS and cancer: Our study and others’ work suggest that multi-axis metabolic targeting (e.g., simultaneous inhibition of ASNS and glutaminase, or ASNS and autophagy) may provide synergistic benefit and prevent resistance by starving cancer cells of compensatory pathways.